ArticleMolecular therapy : the journal of the American Society of Gene Therapy2009
Converting tumor-specific markers into reporters of oncolytic virus infection.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 17 citations in OpenAlex.
- Article
- Measles Virus-Based Genetic Modifications: Progress in Hematological Malignancy Treatment.OncoTargets and therapy · 2025Review
- Live Attenuated Measles Virus Vaccine ExpressingMolecular therapy oncolytics · 2020Article
- Oncolytic Viruses for Multiple Myeloma Therapy.Cancers · 2018Review
- Review
- Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy.Cancer gene therapy · 2015Article
- Review
- Multiplex blood reporters for simultaneous monitoring of cellular processes.Analytical chemistry · 2013Article
- Inhibition of Rho-associated coiled-coil-forming kinase increases efficacy of measles virotherapy.Cancer gene therapy · 2013Article
- Article
- Oncolytic measles virus strains as novel anticancer agents.Expert opinion on biological therapy · 2013Review
- Attenuated oncolytic measles virus strains as cancer therapeutics.Current pharmaceutical biotechnology · 2012Review
- Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon.Journal of virology · 2012Article
- Cancer screening by systemic administration of a gene delivery vector encoding tumor-selective secretable biomarker expression.PloS one · 2011Article
- Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein.Vaccine · 2011Article
- Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model.Breast cancer research and treatment · 2010Article
- Secreted blood reporters: insights and applications.Biotechnology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Preferential killing of transformed cells, while keeping normal cells and organs unharmed, is the main goal of cancer gene therapy. Genetically engineered trackable markers and imaging reporters enable noninvasive monitoring of transduction efficiency and pharmacokinetics of anticancer virotherapeutics. However, none of these reporters can differentiate between infection in the targeted tumors and that in the normal tissue. Thus, we constructed oncolytic measles virus (MV) armed with a human light immunoglobulin chain reporter gene for the treatment of multiple myeloma (MM). Excessive production of monoclonal immunoglobulin is a key characteristic and marker for diagnostics of MM. Once expressed in infected target cells, vector-encoded lambda protein recombines with myeloma IgG-kappa immunoglobulin creating a unique IgG-kappa/lambda. A modified immunoassay technique allows precise quantification of converted marker molecules. Only antibody producing cells were able to assemble this chimeric immunoglobulin molecule, whereas other cells secreted only free lambda light chain. Human myeloma xenografts inoculated with lambda chain expressing MV secreted converted IgG-kappa/lambda in the plasma of tumor bearing animals and elevated reporter levels correlated with response to the therapy. This is the first report of a gene therapy vector engineered to discriminate between infection in malignant and normal cells by molecular modification of a tumor-specific protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.